Source - SMW
GlaxoSmithKline said Friday its ViiV Healthcare joint venture with Pfizer had recorded positive results from two clinical trials of an injectable two-drug regime for the treatment of HIV.   
 
The trials had met their primary endpoints, showing that the combination of ViiV Healthcare's cabotegravir and Janssen's rilpivirine, when injected every four weeks had 'similar efficacy, safety and tolerability to a daily oral three-drug regimen for the treatment of HIV,' John C. Pottage, Jr., M.D., Chief Scientific and Medical Officer of ViiV Healthcare.   
 
'We are also encouraged by patient preference data showing that nearly all participants who switched to the long-acting injectable regimen preferred it over their prior oral therapy.'
 
  'If approved, this two-drug regimen would give people living with HIV one month between each dose of antiretroviral therapy, changing HIV treatment from 365 dosing days per year, to just 12. We look forward to submitting applications to regulatory authorities later this year.'